Cellectis Stock Drops 6% Midday After Post-ASH Congress Surge
The stock of French biotech company Cellectis declined by 6.02% at midday on Friday, December 12, 2025, reaching 4.295 euros after closing at 4.57 euros the previous day. This decline occurred amid moderate trading volumes with 0.31% of the capital traded since the opening. The session is part of a consolidation movement following the strong gains recorded in previous days, driven by the presentation of encouraging clinical results at the ASH Congress in Orlando. Over a week, the stock still shows a gain of 1.3%, while medium and long-term performances remain remarkable with an increase of 53.94% over three months and a surge of 133.2% over twelve months.
Post-Surge Correction Observed
The correction observed this Friday follows several consecutive sessions of gains fueled by the announcement of promising clinical data. On December 8, Cellectis announced at the 67th Annual Congress of the American Society of Hematology in Orlando preliminary results from the phase 1 NATHALI-01 clinical trial evaluating eti-cel, with an overall response rate of 88% and a complete response rate of 63%. This announcement had propelled the stock from 4.02 euros on December 10 to 4.57 euros on December 11, a cumulative increase of more than 13% in two sessions. The current decline appears as a natural profit-taking movement after this surge, with investors adjusting their positions in a context of low volumes. The stock now trades at 4.295 euros, a level still significantly above its reference moving averages. The MM50 is at 3.61 euros and the MM200 at 2.21 euros, placing the price respectively 19% and 94.3% above these key thresholds. This configuration confirms that the medium and long-term upward trend remains intact despite today's correction. However, the stock has lost the major resistance threshold of 4.57 euros breached the previous day, which corresponded to the recent closing high.
Eti-cel: A Promising Candidate
Eti-cel is the first dual CAR allogeneic product candidate simultaneously targeting CD20 and CD22, developed for patients with relapsed or refractory non-Hodgkin's lymphoma after at least two lines of treatment. The company plans to begin patient recruitment in the IL-2 cohort in the first quarter of 2026, with a presentation of the full phase 1 data expected in 2026. These upcoming clinical milestones are potential catalysts for the stock in the coming quarters, enhancing visibility on the Parisian company's pipeline. Today's decline does not undermine the positive momentum established over several months. The biotech, specializing in genome editing and allogeneic CAR-T therapies, benefits from a marked resurgence of investor interest in its clinical advancements. The high volatility over a month, established at 24.30%, reflects the wide variations characteristic of biotechnological values in clinical development phase, where each data announcement can generate significant movements. The beta of 0.66 also indicates a moderate sensitivity to general market fluctuations.
Technical Indicators Suggest Continued Upside
The RSI stands at 61, in a slightly positive zone but not reaching an overbought situation, suggesting that the upward movement could resume without excessive tension. This momentum indicator signals that the stock still has room for progression before entering a technically overheated zone. The Bollinger Bands frame the stock between 3.51 euros and 4.77 euros, placing the current price in the upper middle part of the corridor, which leaves room for movement extension in both directions. The MACD displays a slightly negative histogram at -0.02, with the MACD line at 0.24 very close to its signal line at 0.26. This convergence reflects a short-term hesitation phase, consistent with the consolidation movement observed in the session. The major support threshold is now at 2.86 euros, well below the current level, offering a significant safety cushion. The CMF indicator at 0.16 confirms positive cash flows despite today's decline, while the negative OBV at -144,709 reflects a history of capital outflows contrasting with the recent dynamic. The overall technical configuration remains favorable for a continuation of the upward movement once the consolidation is completed.
